Advances in Safety of Thyroid Suppression Therapy in Differentiated Thyroid Carcinoma

doi:10.12114/j.issn.1007-9572.2019.00.117

Abstract

Abstract: The differentiated thyroid cancer （DTC） is one of the most common malignancies in adults throughout the world.Thyrotropin （TSH） suppression therapy is recommended as a non-surgical treatment for DTC with promising recurrence-reducing effect by international guidelines.However，little was discussed about the safety of the therapy，especially the long-term ones.We narratively reviewed the potential safety concerns of TSH suppression therapy in the cardiovascular，skeletal，neurological and metabolic systems.
Thyroid neoplasms；Thyrotropin；Atrial fibrillation；Osteoporosis；Review

摘要： 分化型甲状腺癌已经成为目前全球最常见的恶性肿瘤之一。促甲状腺素（TSH）抑制治疗作为其术后重要的非手术治疗方法之一，具有肯定的减少肿瘤复发的作用，被国内外主流指南推荐，但其安全性，特别是长期安全性问题讨论较少。本文结合临床研究证据，从心血管、骨代谢、神经、精神系统及糖脂代谢等方面对TSH抑制治疗的潜在安全性进行综述。

关键词: 甲状腺肿瘤, 促甲状腺素, 心房颤动, 骨质疏松, 综述

LIU Shuhuan,TIAN Haoming,LI Sheyu. Advances in Safety of Thyroid Suppression Therapy in Differentiated Thyroid Carcinoma　[J]. Chinese General Practice, 2020, 23(11): 1333-1337. DOI: 10.12114/j.issn.1007-9572.2019.00.117.
刘述欢,田浩明,李舍予. 促甲状腺素抑制治疗分化型甲状腺癌的安全性研究进展[J]. 中国全科医学, 2020, 23(11): 1333-1337. DOI: 10.12114/j.issn.1007-9572.2019.00.117.

References

［1］BRAY F，FERLAY J，SOERJOMATARAM I，et al．Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］．CA Cancer J Clin，2018，68（6）：394-424．DOI：10.3322/caac.21492.
［2］李斐，李舍予.全球甲状腺癌疾病负担［J］．中国全科医学，2018，21（26）：3155-3159．DOI：10.12114/j.issn.1007-9572.2018.00.174.
LI F，LI S Y.Global burden of thyroid cancer［J］．Chinese General Practice，2018，21（26）：3155-3159．DOI：10.12114/j.issn.1007-9572.2018.00.174.
［3］BIONDI B，COOPER D S.Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer［J］．Thyroid，2010，20（2）：135-146．DOI：10.1089/thy.2009.0311.
［4］JIA Q，LI X，LIU Y，et al．Incidental thyroid carcinoma in surgery-treated hyperthyroid patients with Graves' disease：a systematic review and meta-analysis of cohort studies［J］．Cancer Manaq Res，2018，10：1201-1207．DOI：10.2147/CMAR.S164210.
［5］高明.甲状腺结节和分化型甲状腺癌诊治指南［J］．中国肿瘤临床，2012，28（17）：1249-1272．DOI：10.3969.issn.1000-8179.2012.17.001.http://www.cnki.com.cn/Article/CJFDTotal-ZGZL201217004.htm.
［6］PERROS P，BOELAERT K，COLLEY S，et al．Guidelines for the management of thyroid cancer［J］．Clin Endocrinol （Oxf），2014，81（Suppl 1）：1-122．DOI：10.1111/cen.12515.
［7］HAUGEN B R，ALEXANDER E K，BIBLE K C，et al．2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer：the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer［J］．Thyroid，2016，26（1）：1-133．DOI：10.1089/thy.2015.0020.
［8］XIA Q，DONG S，BIAN P D，et al．Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma［J］．Eur Arch Otorhinolaryngol，2016，273（4）：1037-1043．DOI：10.1007/s00405-015-3564-2.
［9］JABBAR A，PINGITORE A，PEARCE S H S，et al．Thyroid hormones and cardiovascular disease［J］．Nat Rev Cardiol，2017，14（1）：39-55．DOI：10.1038/nrcardio.2016.174.
［10］VIGARIO P S，CHACHAMOVITZ D S，TEIXEIRA P F，et al．Impaired functional and hemodynamic response to graded exercise testing and its recovery in patients with subclinical hyperthyroidism［J］．Arq Bras Endocrinol Metabol，2011，55（3）：203-212.
［11］CASU M，CAPPI C，PATRONE V，et al．Sympatho-vagal control of heart rate variability in patients treated with suppressive doses of L-thyroxine for thyroid cancer［J］．Eur J Endocrinol，2005，152（6）：819-824．DOI：10.1530/eje.1.01918.
［12］PAJAMAKI N，METSO S，HAKALA T，et al．Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer［J］．Clin Endocrinol （Oxf），2017，88（2）：303-310．DOI：10.1111/cen.13519.
［13］ABONOWARA A，QURAISHI A，SAPP J L，et al．Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer［J］．Clin Invest Med，2012，35（3）：E152．DOI：10.25011/cim.v35i3.16591.
［14］COLLET T H，GUSSEKLOO J，BAUER D C，et al．Subclinical hyperthyroidism and the risk of coronary heart disease and mortality［J］．Arch Intern Med，2012，172（10）：799-809．DOI：10.1001/archinternmed.2012.402.
［15］FLORIANI C，GENCER B，COLLET T，et al．Subclinical thyroid dysfunction and cardiovascular diseases：2016 update［J］．Eur Heart J，2018，39（7）：503-507．DOI：10.1093/eurheartj/ehx050.
［16］SHARGORODSKY M，SEROV S，GAVISH D，et al．Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma［J］．Thyroid，2006，16（4）：381-386．DOI：10.1089/thy.2006.16.381.
［17］GAZDAG A，NAGY E V，ERDEI A，et al．Aortic stiffness and left ventricular function in patients with differentiated thyroid cancer［J］．J Endocrinol Invest，2015，38（2）：133-142．DOI：10.1007/s40618-014-0143-0.
［18］KLEIN HESSELINK E N，VAN DER HORST-SCHRIVERS A N A，VAN DER HORST I C C，et al．NT-proBNP is increased in differentiated thyroid carcinoma patients and may predict cardiovascular risk［J］．Clin Biochem，2017，50（12）：696-702．DOI： 10.1016/j.clinbiochem.2017.02.020.
［19］BALIRAM R，SUN L，CAO J，et al．Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling［J］．J Clin Invest，2012，122（10）：3737-3741．DOI：10.1172/JCI63948.
［20］WESCHE M F，TIEL-V-BUUL M M，LIPS P，et al．A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter［J］．J Clin Endocrinol Metab，2001，86（3）：998-1005．DOI：10.1210/jcem.86.3.7244.
［21］TOIVONEN J，TAHTELA R，LAITINEN K，et al．Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy［J］．Eur J Endocrinol，1998，138（6）：667-673．DOI：10.1530/eje.0.1380667.
［22］KNUDSEN N，FABER J，SIERBAEK-NIELSEN A，et al．Thyroid hormone treatment aiming at reduced，but not suppressed，serum thyroid-stimulating hormone levels in nontoxic goitre：effects on bone metabolism amongst premenopausal women［J］．J Intern Med，1998，243（2）：149-154．DOI：10.1046/j.1365-2796.1998.00258.x.
［23］ITO M，MIYAUCHI A，HISAKADO M，et al．Biochemical markers reflecting thyroid function in athyreotic patients on levothyroxine monotherapy［J］．Thyroid，2017，27（4）：484-490．DOI：10.1089/thy.2016.0426.
［24］SUGITANI I，FUJIMOTO Y.Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma：a prospective controlled study［J］．Surgery，2011，150（6）：1250-1257．DOI：10.1016/j.surg.2011.09.013.
［25］WANG L Y，SMITH A W，PALMER F L，et al．Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma［J］．Thyroid，2015，25（3）：300-307．DOI： 10.1089/thy.2014.0287.
［26］SHIN D W，SUH B，LIM H，et al．J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients：a retrospective cohort study［J］．J Bone Miner Res，2018，33（6）：1037-1043．DOI：10.1002/jbmr.3407.
［27］KVETNY J，ELLERVIK C，BECH P.Is suppressed thyroid-stimulating hormone （TSH） associated with subclinical depression in the Danish General Suburban Population Study?［J］．Nord J Psychiatry，2015，69（4）：282-286．DOI：10.3109/08039488.2014.972454.
［28］BLUM M R，WIJSMAN L W，VIRGINI V S，et al．Subclinical thyroid dysfunction and depressive symptoms among the elderly：a prospective cohort study［J］．Neuroendocrinology，2016，103（3/4）：291-299．DOI：10.1159/000437387.
［29］AUBERT C E，BAUER D C，DA COSTA B R，et al．The association between subclinical thyroid dysfunction and dementia：the health，aging and body composition （health ABC） study［J］．Clin Endocrinol（Oxf），2017，87（5）：617-626．DOI：10.1111/cen.13458.
［30］BENSENOR I M，LOTUFO P A，MENEZES P R，et al．Subclinical hyperthyroidism and dementia：the sao paulo ageing & health study （SPAH）［J］．BMC Public Health，2010，10（1）：298．DOI：10.1186/1471-2458-10-298.
［31］HU Y，WANG Z，GUO Q，et al．Is thyroid status associated with cognitive impairment in elderly patients in China?［J］．BMC Endocrine Disorders，2016，16（1）：11．DOI：10.1186/s12902-016-0092-z.
［32］RIEBEN C，SEGNA D，DA COSTA B R，et al．Subclinical thyroid dysfunction and the risk of cognitive decline：a meta-analysis of prospective cohort studies［J］．J Clin Endocrinol Metab，2016，101（12）：4945-4954．DOI：10.1210/jc.2016-2129.
［33］JARACZ J，KUCHARSKA A，RAJEWSKA-RAGER A，et al．Cognitive functions and mood during chronic thyrotropin-suppressive therapy with L-thyroxine in patients with differentiated thyroid carcinoma［J］．J Endocrinol Invest，2012，35（8）：760-765．DOI：10.3275/8013.
［34］MOON J H，AHN S，SEO J，et al．The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma［J］．J Clin Endocrinol Metab，2014，99（10）：3782-3789．DOI：10.1210/jc.2013-4454.
［35］熊健哲，王敏哲.甲状腺功能亢进症糖代谢紊乱机制的研究进展［J］．世界最新医学信息文摘，2018，18（72）：132-134．DOI：10.19613/j.cnki.1671-3141.2018.72.055.http://www.cnki.com.cn/Article/CJFDTotal-WMIA201872058.htm.
［36］RACATAIANU N，LEACH N，BONDOR C I，et al．Thyroid disorders in obese patients.Does insulin resistance make a difference?［J］．Arch Endocrinol Metab，2017，61（6）：575-583．DOI：10.1590/2359-3997000000306.
［37］MARATOU E，HADJIDAKIS D J，PEPPA M，et al．Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism［J］．Eur J Endocrinol，2010，163（4）：625-630．DOI： 10.1530/EJE-10-0246.
［38］REZZONICO J，NIEPOMNISZCZE H，REZZONICO M，et al．The association of insulin resistance with subclinical thyrotoxicosis［J］．Thyroid，2011，21（9）：945-949．DOI：10.1089/thy.2010.0402.
［39］HEEMSTRA K A，SMIT J W，EUSTATIA-RUTTEN C F，et al．Glucose tolerance and lipid profile in long term exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism，a randomised controlled trial［J］．Clin Endocrinol（Oxf），2006，65（6）：737-744．DOI：10.1111/j.1365-2265.2006.02660.x.
［40］BEL LASSEN P，KYRILLI A，LYTRIVI M，et al．Total thyroidectomy：a clue to understanding the metabolic changes induced by subclinical hyperthyroidism?［J］．Clin Endocrinol（Oxf），2017，86（2）：270-277．DOI：10.1111/cen.13237.
［41］WOOD-ALLUM C A，SHAW P J.Thyroid disease and the nervous system［J］．Handb Clin Neurol，2014，120：703-735.
［42］GREENLUND L J，NAIR K S，BRENNAN M D.Changes in body composition in women following treatment of overt and subclinical hyperthyroidism［J］．Endocr Pract，2008，14（8）：973-978．DOI：10.4158/EP.14.8.973.
［43］JANSSEN I，HEYMSFIELD S B，ROSS R.Low relative skeletal muscle mass （sarcopenia） in older persons is associated with functional impairment and physical disability［J］．J Am Geriatr Soc，2002，50（5）：889-896．DOI：10.1046/j.1532-5415.2002.50216.x.